Premium
Potential impact of nonavalent HPV vaccine in the prevention of high‐grade cervical lesions and cervical cancer in Portugal
Author(s) -
Pista Angela,
Oliveira Carlos Freire,
Lopes Carlos,
Cunha Maria J.
Publication year - 2017
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12243
Subject(s) - medicine , cervical intraepithelial neoplasia , cervical cancer , human papillomavirus , hpv infection , gynecology , oncology , cancer
Abstract Objective To estimate the potential impact of the nonavalent HPV vaccine for high‐grade cervical lesions and invasive cervical cancer ( ICC ) in Portugal. Methods The present secondary analysis used data collected in the CLEOPATRE II study on the prevalence of HPV 6/11/16/18/31/33/45/52/58 among female patients aged 20–88 years. The prevalence of HPV types in patients with cervical intraepithelial neoplasia ( CIN ) grades 2/3 and ICC was examined. Results Data were included from 582 patients. There were 177, 341, and 64 patients with CIN 2, CIN 3, and ICC , respectively, and 169 (95.5%), 339 (99.4%), and 62 (96.9) of them had HPV infections. Of patients with HPV infections, HPV 16, 18, 31, 33, 45, 52, and 58 infections were identified in 150 (88.8%), 329 (97.1%), and 60 (96.8%) patients with CIN 2, CIN 3, and ICC , respectively. HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58 were identified in 540 (94.7%) of the patients with HPV infections. Conclusion The addition of the five HPV genotypes included in the nonavalent HPV vaccine ( HPV 31/33/45/52/58) could result in the new HPV vaccine preventing 94.7% of CIN 2/3 and ICC occurrences.